Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
About this item
Full title
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Critical care (London, England), 2020-07, Vol.24 (1), p.396-396, Article 396
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Alternative Titles
Full title
Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_75e33340e6794bdbab6318c58afd289e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_75e33340e6794bdbab6318c58afd289e
Other Identifiers
ISSN
1364-8535
E-ISSN
1466-609X,1364-8535,1366-609X
DOI
10.1186/s13054-020-03097-w
